Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
93.73
-0.49 (-0.52%)
At close: Dec 5, 2024, 4:00 PM
92.22
-1.51 (-1.61%)
After-hours: Dec 5, 2024, 6:19 PM EST
Nuvalent Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
92
Market Cap
6.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 147.66B |
Bausch + Lomb | 4.68B |
Jazz Pharmaceuticals | 3.99B |
Lantheus Holdings | 1.50B |
Merit Medical Systems | 1.33B |
Halozyme Therapeutics | 947.36M |
Corcept Therapeutics | 628.56M |
Blueprint Medicines | 434.42M |
NUVL News
- 9 days ago - Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference - PRNewsWire
- 23 days ago - Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Nuvalent: Promising Data Keeps Validating Pipeline And Platform - Seeking Alpha
- 2 months ago - Nuvalent Announces Closing of Upsized Public Offering of Common Stock - PRNewsWire
- 2 months ago - Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases - Seeking Alpha
- 2 months ago - Nuvalent Announces Pricing of Upsized Public Offering of Common Stock - PRNewsWire
- 2 months ago - Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity - Benzinga
- 2 months ago - Cancer Biotech Nuvalent's Stock Jumps on Positive Data - Barrons